Masayoshi Nogami

No ORCID on file · 5 papers in corpus · active 2024-2026

Study types

  • rct 3
  • other 2

Condition tags

  • endometriosis 3
  • dysmenorrhea 2
  • chronic_pelvic_pain 1
  • adenomyosis 1
rct
Efficacy and safety of estetrol (15 mg)/drospirenone (3 mg) combination in a cyclic regimen for the treatment of primary and secondary dysmenorrhea: a multicenter, placebo-controlled, double-blind, randomized study
Fertility and sterility ·doi:10.1016/j.fertnstert.2024.11.003

OBJECTIVE: To evaluate the efficacy and safety of the estetrol (E4) (15 mg)/drospirenone (DRSP) (3 mg) combination in a cyclic regimen in Japanese women with primary and secondary dysmenorrhea. DESIGN: A 16-week, multicenter, randomized, d…

other 2026
Impact of estetrol and drospirenone combination therapy on alleviation of the pelvic pain of endometriosis: a randomized control trial
F&S reports ·doi:10.1016/j.xfre.2025.12.002

OBJECTIVE: To study the impact of estetrol (E4), a novel native estrogen with selective tissue activity, on endometriosis-associated pelvic pain (EAPP) and global impressions of endometriosis pain. DESIGN: Multicenter, randomized, open-lab…

other 2026
Post Hoc Analysis of a Previous Study of Estetrol 15 mg/Drospirenone 3 mg Combination for Dysmenorrhea and Uterine Bleeding in Adenomyosis Patients
Reproductive medicine and biology ·doi:10.1002/rmb2.70021

PURPOSE: To clarify the efficacy and safety of the estetrol 15 mg/drospirenone 3 mg combination among Japanese women with adenomyosis by post hoc analyses of a previous randomized clinical study. METHODS: Post hoc analyses were performed u…

rct 2024
Efficacy and safety of the combination of estetrol 15 mg/drospirenone 3 mg in a cyclic regimen for the treatment of endometriosis-associated pain and objective gynecological findings: a multicenter, placebo-controlled, double-blind, randomized study
Fertility and sterility ·doi:10.1016/j.fertnstert.2024.07.011

OBJECTIVE: To evaluate the efficacy and safety of 24-week cyclic administration of estetrol (E4) (15 mg)/drospirenone (DRSP) (3 mg) in Japanese patients with endometriosis. DESIGN: A 24-week, multicenter, randomized, double-blind, placebo-…

rct 2024
Impact of Estetrol Combined with Drospirenone on Blood Coagulation and Fibrinolysis in Patients with Endometriosis: A Multicenter, Randomized, Open-Label, Active-Controlled, Parallel-Group Study
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis ·doi:10.1177/10760296241286514

Venous thromboembolism is a serious safety concern in women using combined oral contraceptives; ethinyl estradiol (EE) is widely used as an estrogen. Estetrol (E4) is a native estrogen with selective tissue activity and exclusively produced…